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high interindividual variation in expression were involved 
include liver regeneration, inflammatory responses, mito-
chondrial stress responses, hepatocarcinogenesis, cell cycle, 
and drug efficacy. Additionally, the interindividual variation 
in the expression of these genes could be associated with the 
variability in expression levels of hydroxyl/methoxy-APAP 
and C8H13O5N-APAP-glucuronide. The before-mentioned 
metabolites or their derivatives have also been reported in 
blood of humans exposed to therapeutic APAP doses. Possi-
bly these findings can contribute to elucidating the causative 
factors of interindividual susceptibility toward APAP.
Keywords Interindividual variation · Primary human 
hepatocytes · DNA methylation · Gene expression · 
Aflatoxin b1 · Benzo(a)pyrene
Introduction
Acetaminophen (APAP) is one of the most commonly used 
analgesics/antipyretics worldwide. Thereby, it is a readily 
available over-the-counter drug. Apart from its beneficial 
effects as a pharmaceutical, APAP is also the most common 
cause of acute liver toxicity in Europe and the USA (Lee 
2007). Cytochrome P450 enzymes in the liver metabolize 
APAP to the oxidative metabolite N-acetyl-p-benzoquinone 
imine (NAPQI), which is thought to cause the toxic effects 
of APAP through protein adduct formation, leading to oxida-
tive stress and finally liver damage (Dahlin et al. 1984a). The 
molecular mechanism behind further progression of APAP 
toxicity still is not fully elucidated; the involvement of multi-
ple mechanisms of toxicity, like inflammatory responses and 
oxidative stress, has been suggested (Jaeschke et al. 2012).
The main body of our knowledge on the toxicological, 
or more specific hepatotoxic, mechanisms of compounds, 
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including APAP, is based on data collected from stud-
ies using animal models (Hinson et al. 2010). However, 
increasing criticism on the usability and applicability of 
animal data to the human situation has developed over the 
last years (Greek and Menache 2013). Therefore, there is 
a growing need for human in vitro models such as hepatic 
cell lines, liver slices, or primary hepatocytes cultures, to 
facilitate human-based research.
Large interindividual differences in response to xeno-
biotic exposure between humans have been documented 
(Court et al. 2001). In the domains of toxicology/pharma-
cology, many attempts are being undertaken to gain a bet-
ter understanding of the factors that are causative of this 
interindividual variation. Environmental factors as well as 
genetic factors have been proposed to contribute to the var-
iation in drug responses between human individuals. Over 
the last decade, with the rise of the whole genome omics 
techniques, it has become feasible to perform more com-
plete/in-depth analysis of the genomic components contrib-
uting to interindividual variation in the human population 
(Berg 2014).
Also, the metabolism of APAP is known to show large 
interindividual variability (Court et al. 2001). Genetic fac-
tors including many biotransformation-related genes, such 
as UDP-glucuronosyltransferases and cytochrome P450 
enzymes, have been suggested to be causative of the vari-
ation in APAP-induced adverse effects observed between 
individuals (Court et al. 2001; Fisher et al. 2000; Polasek 
et al. 2006; Yasar et al. 2013). While some individuals seem 
to be able to endure APAP doses considerably exceeding 
the recommended maximal daily dose, others are at risk 
of liver toxicity due to APAP much closer to the recom-
mended dose window (Sabate et al. 2011). The relatively 
high frequency of unintentional overdosing has recently led 
the FDA to adjusting recommendations on safe APAP dos-
age use by lowering the maximal therapeutic daily dose and 
decreasing the single dose units of APAP (Turkoski 2010).
However, not only interindividual differences do occur 
at supra-therapeutic doses, but also (sub-) therapeutic doses 
of APAP have been shown to cause interindividual varia-
tion in APAP metabolite levels, as well as in mRNA and 
miRNA expression levels (Jetten et al. 2012). In the same 
study, regulation of biological processes known to be 
related to the liver toxicity response after APAP overdosing 
could be detected at lower and supposedly non-toxic doses.
In this study, we aim at investigating the interindividual 
differences in response to a non-toxic to toxic APAP dose 
range, using an in vitro cell model consisting of primary 
human hepatocytes of several donors. The interindividual 
differences in APAP metabolite formation and gene expres-
sion responses were considered and compared in an attempt 
to pinpoint the factors that could be causative of interindi-
vidual variation in APAP metabolism.
Materials and methods
Cell culture and treatment
Primary human hepatocytes
Cryopreserved PHH of five individuals (see Supplemen-
tary Table 1 for donor demographics) were purchased 
from Life Technologies (Gibco). Cells were cultured in 
12-well plates in a collagen sandwich, according to the 
supplier’s protocol (Invitrogen 2009). The following cul-
ture media were used: cryopreserved hepatocyte recovery 
medium (CHRM, Gibco) for thawing, William’s medium 
E (WME) + Glutamax (Gibco) substituted with 10 % 
FCS (Gibco), 0.02 % penicillin/streptomycin (Gibco), and 
0.1 U/ml insulin (Invitrogen) for seeding/attaching and 
WME + Glutamax substituted with 0.02 % Pen/Strep, 
0.1 U/ml insulin, and 0.02 mg/ml hydrocortisone (Sigma-
Aldrich) for culturing/exposure. After thawing, viability of 
the cells was checked by a trypan blue (CAS no. 72-57-1, 
Sigma-Aldrich) exclusion test as instructed in the suppli-
er’s protocol (Invitrogen 2009). All viability scores were 
in accordance with those listed by the supplier. Hepato-
cytes were exposed for 24 h to 0, 0.2, 2, or 10 mM APAP 
(CAS no. 103-90-2, Sigma-Aldrich) dissolved in culture 
medium. The doses, representing no observed effect level 
(NOEL), lowest observed effect level (LOEL = non-
toxic), and toxic dose, respectively, were chosen based 
on the available literature (Bannwarth et al. 2001; Borin 
and Ayres 1989; Critchley et al. 2005; Douglas et al. 1996; 
Kamali 1993; Kienhuis et al. 2009; Portolés et al. 2003; 




QIAzol (0.5 ml, QIAGEN) was used to isolate total RNA 
from all samples according to the manufacturer’s protocol. 
RNA purification was performed with the miRNeasy Mini 
Kit (Qiagen) as instructed by the manufacturer. Next, the 
integrity of the RNA was checked with the Bioanalyzer 
2100 (Agilent).
cDNA preparation/hybridization
From an input of 250 ng RNA, cDNA targets were pre-
pared using the Affymetrix protocol. The procedures as 
recommended by the manufacturer were applied to hybrid-
ize the samples to Affymetrix GeneChip Human Genome 
U133A plus 2 GeneChip arrays. GeneChips were washed 
and stained after hybridization with a fluidics station 
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(Affymetrix) and scanned with a GeneArray scanner (Affy-
metrix). The samples from donor 1 exposed to 10 mM 
APAP did not pass quality control and were therefore 
excluded from further analyses.
Transcriptomic data analysis
The CEL files retrieved in the previous step were subjected 
to an overall quality control, using arrayanalysis.org, and 
all arrays were of high quality (Eijssen et al. 2013). Sub-
sequently, data were RMA-normalized and re-annotated 
using BrainArray’s EntrezGene customCDF_V15.1 (Dai 
et al. 2005; Lim et al. 2012). Probes with low signal-to-
noise ratio (average expression <6) were excluded from 
further analyses as a data-cleanup step.
Metabolomic sample preparation
Culture medium from the cells was collected after 24 h and 
stored at −80 °C until extraction. To extract the metabo-
lites, 6 ml of ice-cold acetone was added to 1.5 ml of 
medium in a 10-ml glass tube. The solution was vortexed 
for 30 s, kept on ice for 12 min, and then centrifuged for 
15 min at 2800 rpm at 4 °C. The supernatant was trans-
ferred into a 10-ml glass tube and dried under nitrogen. 
To concentrate the semi-polar metabolites contained in the 
medium, SPE C18 columns (C18, 500 mg, 3 ml, Bond-
Elut, VARIAN) were used. The SPE C18 column was 
conditioned by running it with methanol including 0.5 % 
of formic acid (1 ml twice) and MilliQ including 0.5 % 
of formic acid (1 ml twice). Once the dried pellet was re-
suspended in 1 ml of MilliQ (with 0.5 % formic acid), it 
was applied to the column. The column was then washed 
twice with 1 ml of MilliQ, after which the components of 
interest were eluted with 1 ml of methanol and dried under 
nitrogen. For U-HPLC-Orbitrap analysis, the dried polar 
fraction was re-suspended in 400 μl of MilliQ with 0.1 % 
formic acid.
U‑HPLC‑Orbitrap MS analysis
Experimental setups and procedures as described before 
have been used with some slight modifications as defined 
below (Lommen 2009; Lommen et al. 2011; Ruiz-Aracama 
et al. 2011). The gradient was similar to the one used in 
Jetten et al. (2012) with small modifications. The initial 
eluent composition, 100 % A, was changed to 85% A and 
15 % B in 15 min. Afterward, the composition of B was 
increased to 30 % in 10 min and subsequently increased 
in 3 min to 90 %, remaining at this composition for 5 min 
prior to the next injection. A capillary temperature of 
250 °C with a sheath and auxiliary gas flow of 19 and 7 
arbitrary units were used, respectively.
Metabolomic data analysis
Visual inspection of the three technical replicates of each 
sample showed a high degree of reproducibility. All MS 
data were preprocessed and aligned using the in-house 
developed program, metAlign (Lommen 2009). A targeted 
search for the metabolites of APAP previously described 
in Jetten et al. (2012) was executed. For targeted analy-
ses, Search LCMS, an add-on tool for metAlign, was used 
(Lommen 2009). Briefly, a list of masses of interest was 
composed based on our previous in vivo study with human 
volunteers (Jetten et al. 2012) and some further data avail-
able from mice (Chen et al. 2008a). This list was loaded 
into Search LCMS, which returned the amplitudes of the 
masses of interest.
U-HPLC-Orbitrap MS data were preprocessed as 
described in previous papers (Lommen 2009; Lommen 
et al. 2011) to obtain ultra-precise (sub-ppm) mass data 
(calibration using internal masses and PEG200, PEG300, 
PEG600 as external masses). Metabolites were consid-
ered to be present when retention times were analogous 
to earlier experiments and average accurate masses were 
below ±3 ppm; nearly all average masses of metabolites 
were within 1 ppm. For some metabolites previously not 
found, including hydroxy-APAP, methoxy-APAP, and 
3,3′-biacetaminophen, retention times were related to 
those derived from the literature if possible (Chen et al. 
2008a; Jetten et al. 2012). Metabolite expression levels for 
methoxy-APAP-glucuronide-1/2 and hydroxy-APAP-glu-
tathione in samples of donor 1 exposed to 10 mM APAP 
could unfortunately not be determined due to technical 
issues.
Metabolite visualization
To create a metabolic map based on available literature, a 
pathway visualization tool, PathVisio, was used (Chen et al. 
2008b; Daykin et al. 2002; van Iersel et al. 2008). LC–MS 
data were visualized for each donor and per dose (corrected 
for control levels, 0 mM APAP). Log-transformation of the 
data resulted in range with a minimum of 0 and a maxi-
mum of 5.
Data integration and visualization; interindividual 
variation
Expression data (log2-scaled intensities) of all genes 
passing the selection as described under ‘transcriptomic 
data analysis’ and levels of all of the identified metabo-
lites were plotted against APAP dose per donor (X-axis: 
dose 0, 0.2, 2, and 10 mM APAP; Y-axis: log-scaled gene 
expression/metabolite levels; line: donor, n = 5) using R 
2.15.3 (R Core Team 2013). For clarification purposes, a 
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representative plot is provided in Supplementary Figure 1. 
To estimate the correlation in APAP dose response between 
donors, data points from one donor were compared to the 
data points of all other donors using a Pearson-based cor-
relation analysis, which resulted in the following compari-
sons: D1–D2, D1–D3, D1–D4, D1–D5, D2–D3, D2–D4, 
D2–D5, D3–D4, D3–D5, and D4–D5. Then, the absolute 
correlation coefficients of each donor were summed to gen-
erate an arbitrary correlation score per donor for each gene/
metabolite (Score D1, Score D2, Score D3, Score D4, and 
Score D5; see supplementary Figure 1). This ‘score’ now 
represents the similarity of a particular donor to all other 
donors in expression response for a particular gene/metabo-
lite following APAP exposure; the donor with the lowest 
score is most aberrant from all other donors (showed the 
least correlation with the other donors). In order to select 
the most variable genes between donors, standard devia-
tions (SD) of the donor scores per gene/metabolite were 
calculated and ranked. The top 1 % ranked genes (score 
SD > 2.52) were selected for further analysis, since these 
exhibit the most interdonor variability (Table 1).
To enable biological interpretation, an overrepresenta-
tion analysis was performed on this set of variable genes, 
using the overrepresentation module of ConsensusPathDB 
(Kamburov et al. 2013). A background list consisting of all 
genes passing the selection as described under ‘transcrip-
tomic data analysis’ was used in this analysis.
Subsequently, the correlation score matrices (see top left 
corner supplementary Figure 1) created for each of the top 
1 % highly variable genes and all metabolites were used to 
find gene expression profiles that match metabolite profiles 
on an individual level. To do so, the interdonor correlations 
for all highly variable genes were correlated with the inter-
donor correlations from all metabolites (Pearson). A cutoff 
of >0.7 was used to define genes of which the difference in 
expression levels mimicked the difference in the metabolite 
levels between donors. The results of this analysis are sum-
marized in supplementary Table 3.
To define genes related to mitochondrial processes, the 
top 1 % variable genes were compared to the mitochondrial 
reference gene set from MITOP2. This is a database which 
provides a list of human mitochondrial proteins linked to 
their gene names found through computational predic-
tion of signaling sequences, but also includes results from 
proteome mapping, mutant screening, expression profil-
ing, protein–protein interaction, and cellular sub-locali-
zation studies (Elstner et al. 2009). The MiMI plugin for 
Cytoscape was used to generate a network for all mitochon-
drial-related genes based on the nearest neighbor analysis 
(Fig. 3; Gao et al. 2009). Only the nearest neighbors shared 




Just over 10,000 genes were screened for interindividual 
variation in their responses toward APAP exposure by cor-
relating their expression over dose. Standard deviations of 
these correlation scores showed a normal distribution. To 
assure that only the most variable genes were used for fur-
ther analyses, and a short list was created of the top 1 % 
most variable genes (see Table 1, n = 99, SD > 2.52).
To define the functionality of the variable genes, an 
overrepresentation analysis was performed, i.e., a network 
consisting of the biological pathways containing the genes 
with the highest variability between donors in response to 
APAP exposure was defined (see Fig. 1). This overrepre-
sentation network could be broken down into several parts; 
one large component appeared constructed of:
•	 A large cluster with toll-like receptors (TLR), c-Jun 
N-terminal kinases (JNK), nuclear factor (NF)-κB, 
interleukin (IL)-1, p38, and cyclin D1-related pathways 
(encircled with striped line).
•	 A smaller cluster around p75 neurotrophin receptor 
(p75 NTR) (encircled with dotted line).
•	 Two more components, involved in ‘Wnt-signaling 
pathway and pluripotency’ and ‘BTG (B cell transloca-
tion gene) family proteins and cell cycle regulation.’
Additional parts consisted of components separated 
from the large cluster on ‘leukotriene metabolism,’ ‘bio-
synthesis of unsaturated fatty acids,’ ‘amino sugar and 
nucleotide sugar metabolism,’ ‘retinoic acid-inducible 
gene 1 (RIG-I), and melanoma differentiation-associ-
ated protein 5 (MDA5)-mediated induction of interferon 
(IFN)-alpha–beta.’
A further network based on mitochondrial-related genes 
form the top 1 % highly variable genes was created using 
next neighbor analysis in Cytoscape Fig. 2. This figure 
shows that transcription factors are the main binding ele-
ment in the response of mitochondrial-related genes, 
showing high interindividual variation in gene expression 
response after APAP exposure.
Metabolomics
A broad spectrum of metabolites was measured in the 
medium, as shown in Supplementary Table 3 and Fig-
ure 3. In general, the variation between individuals was 
lower with respect to metabolite levels when compared to 
the variation in gene expression levels. To define how the 
variability between donors in gene expression is related to 
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Table 1  List of the top 1 % most variable genes based on Pearson correlation analysis
EntrezGeneID Gene name Functional description according to GeneCards
92 ACVR2A Kinase receptor
513 ATP5D Subunit of mitochondrial ATP synthase
595 CCND1 Cyclin family
617 BCS1L Complex III of the mitochondrial respiratory chain
988 CDC5L Cell cycle regulator important for G2/M transition
1545 CYP1B1 Cytochrome P450 superfamily
1611 DAP Mediator of programmed cell death
2669 GEM GTP-binding proteins, receptor-mediated signal transduction
2766 GMPR NADPH-dependent reductive deamination of GMP to IMP
3276 PRMT1 Methyltransferase
4302 MLLT6 Myeloid/lymphoid or mixed-lineage leukemia
4615 MYD88 Myeloid differentiation primary response
5201 PFDN1 Member of the prefolding beta subunit family
5287 PIK3C2B PI3-kinases play roles in signaling pathways involved in cell proliferation, oncogenic transformation, cell 
survival, cell migration, and intracellular protein trafficking
5300 PIN1 Regulation of cell growth, genotoxic, and other stress responses, the immune response, induction and mainte-
nance of pluripotency, germ cell development, neuronal differentiation, and survival
5523 PPP2R3A Negative control of cell growth and division
5550 PREP Maturation and degradation of peptide hormones and neuropeptides
5584 PRKCI Protective role against apoptotic stimuli, is involved in NF-kappa-B activation, cell survival, differentiation, 
and polarity and contributes to the regulation of microtubule dynamics in the early secretory pathway
5696 PSMB8 Apoptosis, may be involved in the inflammatory response pathway
5699 PSMB10 Involved in antigen processing to generate class I-binding peptides
5796 PTPRK Cell growth, differentiation, mitotic cycle, and oncogenic transformation
6612 SUMO3 Posttranslationally modify numerous cellular proteins and affect their metabolism and function, such as 
nuclear transport, transcriptional regulation, apoptosis, and protein stability
6942 TCF20 Stimulates the activity of various transcriptional activators such as JUN, SP1, PAX6, and ETS1, suggesting a 
function as a co-activator
7264 TSTA3 Cell–cell interactions, including cell–cell recognition; in cell–matrix interactions; in detoxification processes
7572 ZNF24 Transcription repressor activity
7965 AIMP2 Functions as a pro-apoptotic factor
8270 LAGE3 ???
8310 ACOX3 Desaturation of 2‑methyl branched fatty acids in peroxisomes
8985 PLOD3 Hydroxylation of lysyl residues in collagen-like peptides
9343 EFTUD2 A component of the spliceosome complex which processes precursor mRNAs to produce mature mRNAs
9361 LONP1 Mediates the selective degradation of misfolded, unassembled, or oxidatively damaged polypeptides in the 
mitochondrial matrix assembly of inner membrane protein complexes and participates in the regulation of 
mitochondrial gene expression and maintenance of the integrity of the mitochondrial genome
9470 EIF4E2 EIF4E2 gene promoter protein synthesis and facilitates ribosome binding by inducing the unwinding of the 
mRNA secondary structures
10093 ARPC4 Regulation of actin polymerization and together with an activating nucleation-promoting factor (NPF) medi-
ates the formation of branched actin networks
10189 THOC4 Molecular chaperone. It is thought to regulate dimerization, DNA binding, and transcriptional activity of basic 
region-leucine zipper (bZIP) proteins
10313 RTN3 Involved in membrane trafficking in the early secretory pathway
10422 UBAC1 Required for poly-ubiquitination and proteasome-mediated degradation of CDKN1B during G1 phase of the 
cell cycle
10598 AHSA1 May affect a step in the endoplasmic reticulum to Golgi trafficking
10807 SDCCAG3 May be involved in modulation of TNF response
10899 JTB Required for normal cytokinesis during mitosis. Plays a role in the regulation of cell proliferation
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Table 1  continued
EntrezGeneID Gene name Functional description according to GeneCards
11068 CYB561D2 Acting as an ubiquitin-conjugating enzyme, involved in the regulation of exit from mitosis, cell cycle, protein, 
ubiquitin-dependent proteolysis, electron transport
11131 CAPN11 Remodeling of cytoskeletal attachments to the plasma membrane during cell fusion and cell motility, pro-
teolytic modification of molecules in signal transduction pathways, degradation of enzymes controlling 
progression through the cell cycle, regulation of gene expression, substrate degradation in some apoptotic 
pathways, and an involvement in long-term potentiation
11142 PKIG PKA inhibitors; protein kinase A has several functions in the cell, including regulation of glycogen, sugar, and 
lipid metabolism
11252 PACSIN2 Involved in linking the actin cytoskeleton with vesicle formation by regulating tubulin polymerization
11332 ACOT7 Catalyze the hydrolysis of acyl‑CoAs to the free fatty acid and coenzyme A (CoASH), providing the potential 
to regulate intracellular levels of acyl‑CoAs, free fatty acids, and CoASH
23243 ANKRD28 Involved in the recognition of phosphoprotein substrates
23325 KIAA1033 Plays a key role in the fission of tubules that serve as transport intermediates during endosome sorting
23558 WBP2 Involved in mediating protein–protein interactions through the binding of polyproline ligands
26100 WIPI2 Probable early component of the autophagy machinery being involved in formation of preautophagosomal 
structures and their maturation into mature phagosomes
26505 CNNM3 Probable metal transporter
26520 TIMM9 Mediate the import and insertion of hydrophobic membrane proteins into the mitochondrial inner membrane
27075 TSPAN13 Mediate signal transduction events that play a role in the regulation of cell development, activation, growth, 
and motility
29105 C16orf80 ???
29927 SEC61A1 Plays a crucial role in the insertion of secretory and membrane polypeptides into the ER
50640 PNPLA8 Phospholipases which catalyze the cleavage of fatty acids from membrane phospholipids
51094 ADIPOR1 Regulates fatty acid catabolism and glucose levels
51491 NOP16 Involved in ribosome biogenesis
51504 TRMT112 Participates in both methylation of protein and tRNA species
51523 CXXC5 Required for DNA damage-induced ATM phosphorylation, p53 activation, and cell cycle arrest. Involved in 
myelopoiesis
51706 CYB5R1 Involved in desaturation and elongation of fatty acids, cholesterol biosynthesis, drug metabolism, and, in 
erythrocyte, methemoglobin reduction
54187 NANS Functions in the biosynthetic pathways of sialic acids
54606 DDX56 Implicated in a number of cellular processes involving alteration of RNA secondary structure such as transla-
tion initiation, nuclear and mitochondrial splicing, and ribosome and spliceosome assembly. May play a role 
in later stages of the processing of the preribosomal particles, leading to mature 60S ribosomal subunits. Has 
intrinsic ATPase activity
54941 RNF125 E3 ubiquitin-protein ligase that acts as a positive regulator of T cell activation
55062 WIPI1 May play a role in autophagy
55111 PLEKHJ1 ??? phospholipid binding
55238 SLC38A7 Mediates sodium-dependent transport of amino acids
55315 SLC29A3 Plays a role in cellular uptake of nucleosides, nucleobases, and their related analogs
55647 RAB20 Plays a role in the maturation and acidification of phagosomes that engulf pathogens
55700 MAP7D1 Mitotic spindle protein and member of the MAP7 (microtubule-associated protein 7) family of proteins
55743 CHFR Functions in the antephase checkpoint by actively delaying passage into mitosis in response to microtubule 
poisons
55898 UNC45A Plays a role in cell proliferation and myoblast fusion, binds progesterone receptor and HSP90, and acts as a 
regulator of the progesterone receptor chaperoning pathway
56005 C19orf10 ???
56267 CCBL2 Encodes an aminotransferase that transaminates kynurenine to form kynurenic acid
56910 STARD7 ???
57409 MIF4GD Functions in replication-dependent translation of histone mRNAs
64754 SMYD3 Histone methyltransferase
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the variability in metabolite level in these same donors, a 
Pearson-based correlation analysis between the top 1 % 
variable genes and all metabolites was performed (cutoff 
R2 > 0.7). Out of the 99 most variable genes, 91 could be 
linked to the variation in metabolites on an individual level, 
meaning that these 91 genes can at least partially explain 
the interindividual variation observed in metabolites. In 
particular, hydroxy-APAP, methoxy-APAP, and the tenta-
tively identified metabolite C8H13O5N-APAP-glucuronide 
showed strong correlations with genes on an individual 
level (n = 36, 36, and 51 correlating genes, respectively). 
Interestingly, C8H13O5N-APAP-glucuronide has previ-
ously been reported by Jetten et al. (2012) as a novel APAP 
metabolite, which could be detected in the in vivo human 
situation after low-dose APAP exposure. This metabolite 
could thus be confirmed in the current study in an in vitro 
human situation consisting of primary human hepatocytes. 
Furthermore, a mass tentatively assigned to 3,3′-biaceta-
minophen (not detected previously) has also been found. 
3,3′-biacetaminophen has been suggested to result from 
NAPQI reacting with APAP and is considered a reactive 
oxygen species (ROS) product (Chen et al. 2008a).
Discussion
The aim of this study is to evaluate the interindividual dif-
ferences in gene expression changes and APAP metabolite 
formation in primary human hepatocytes of several donors 
(n = 5) exposed to a non-toxic to toxic APAP dose range.
Interindividual variation in gene expression is a very 
common phenomenon; therefore, we have focused on the 
gene expression changes that are most different between 
individuals in response to APAP exposure. To do so, we 
Table 1  continued
EntrezGeneID Gene name Functional description according to GeneCards
64787 EPS8L2 Is thought to link growth factor stimulation to actin organization, generating functional redundancy in the 
pathways that regulate actin cytoskeletal remodeling
64949 MRPS26 Mammalian mitochondrial ribosomal proteins are encoded by nuclear genes and help in protein synthesis 
within the mitochondrion
66036 MTMR9 Thought to have a role in the control of cell proliferation
79056 PRRG4 ??? Calcium ion binding
80227 PAAF1 Involved in regulation of association of proteasome components
80775 TMEM177 ???
89870 TRIM15 ???
91663 MYADM ??? Regulates the connection between the plasma membrane and the cortical cytoskeleton and so can control 
the endothelial inflammatory response
114971 PTPMT1 Is an essential intermediate in the biosynthetic pathway of cardiolipin, a mitochondrial‑specific phospholipid 
regulating the membrane integrity and activities of the organelle
124583 CANT1 Functions as a calcium-dependent nucleotidase 
127687 C1orf122 ???
135932 TMEM139 ???
140465 MYL6B Regulatory light chain of myosin
140606 SELM May function as a thiol-disulfide-oxidoreductase that participates in disulfide bond formation
147007 TMEM199 ???
151613 TTC14 ??? RNA binding
155066 ATP6V0E2 Play an important role in processes such as receptor-mediated endocytosis, protein degradation, and coupled 
transport
196383 RILPL2 Involved in cell shape and neuronal morphogenesis, positively regulating the establishment and maintenance 
of dendritic spines
252839 TMEM9 May be involved in intracellular transport
253461 ZBTB38 May be involved in the differentiation and/or survival of late postmitotic neurons




The description of the functionality of the gene has been taken from GeneCards; genes involved in mitochondrial processes according to the 
MITOP2 database are in italic
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have created a short list consisting of the top 1 % most 
different genes based on correlation analysis (n = 99, see 
Table 1). Expression levels of many genes/metabolites 
including, but not limited to cytochrome P450 enzymes, 
glucuronosyltransferases, sulfotransferases, and glu-
tathione S-transferases have been shown to influence the 
biotransformation processes of APAP (Zhao and Pickering 
2011). However, studies in general link baseline expres-
sion levels of these genes to APAP metabolism parameters, 
while in the current study we focus on response parameters 
after APAP exposure in order to explain interindividual 
variability.
To define the biological functionality of the genes with 
the highest variability between individuals (top 1 % list), 
Fig. 1  Network of the top 1 % most variable genes between donors 
after APAP exposure. The network was created based on a gene set 
overrepresentation analysis (ConsensusPathDB). Each node repre-
sents a biological pathway, the size of the node represents the amount 
of genes included in the pathway (bigger diameter = larger # genes), 
the color of the node represents its significance (darker gray = lower 
p value), and the thickness of the edge represents the amount of over-
lap between the connected nodes (thicker line = higher # overlapping 
genes)
Fig. 2  Network of highly variable mitochondrial-related genes. 
Nearest neighbor analysis was performed on all mitochondrial-related 
genes from the top 1 % highly variable gene list. Only the nearest 
neighbors shared by more than one of the variable genes were taken 
into account. Square nodes represent input genes, and round nodes 
represent the shared nearest neighbors
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a network of pathways found by gene set overrepresenta-
tion analysis on this list was created (Fig. 1). This network 
shows a large cluster with TLRs, JNK, NF-κB, IL-1, p38, 
and cyclin D1-related pathways (encircled with striped 
line). TLR, JNK, and NF-κB pathways are all key regula-
tors in the production of cytokines associated with inflam-
matory responses and the early stages of the development 
of hepatocarcinogenesis (Maeda 2010). Furthermore, all 
of the above-mentioned pathways have been associated 
with the process of liver regeneration (Iimuro and Fuji-
moto 2010). Hepatocytes rarely undergo proliferation in 
the liver under normal circumstances. However, prolifera-
tion can be triggered in response to loss of liver mass for 
instance induced by liver resection but also due to toxin-
induced hepatocyte trauma like is the case with APAP. In 
both in vitro and in vivo studies, APAP has been shown to 
induce a persistent activation of JNK adding to hepatocel-
lular necrosis (Gunawan et al. 2006). Cross talk between 
JNK and NF-κB has been proposed as a mechanism 
through which JNK mediates cell death. Matsumura et al. 
(2003) showed that inhibition of NF-κB in the liver by 
APAP leads to amplification of JNK and as such shifts the 
Fig. 3  Schematic visualization 
of APAP metabolic pathway. 
The log-transformed metabo-
lite levels for each donor on at 
each dose corrected for 0 mM 
are visualized. Gray boxes not 
measured/detected. Increase in 
a metabolite is pictured from 
green (no increase, equals a 
numerical value of 0 on a log 
scale) to yellow, orange, and 
red (high increase, maximum 
value = 5 on a log scale). 
Figure adapted from Jetten et al. 
(2012) (color figure online)
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balance from cell survival toward cell death. IL-1 stimu-
lates both the JNK and NF-κB pathways, which increases 
cell signaling and interferes with the cell cycle (Matsu-
zawa et al. 2005; Sanz-Garcia et al. 2013). TLR plays a 
role in the expression of cytokines and hepatomitogens; 
in response to TRL activation, p38 is triggered, leading to 
cytokine- and stress-induced apoptosis (Matsuzawa et al. 
2005; Sanz-Garcia et al. 2013). Finally, it is indicated that 
that NF-κB activation operates on cell growth through cyc-
lin D1 expression (Guttridge et al. 1999; Maeda 2010). 
In acetaminophen-induced liver injury, sustained JNK 
activation, through NF-κB, is essential in inducing apop-
tosis (Hanawa et al. 2008). Furthermore, it is suggested 
that NAPQI-induced damage on its own is not enough to 
cause hepatocyte death after APAP dosing and that activa-
tion of signaling pathways involving JNK is necessary to 
lead to cell death (Hanawa et al. 2008; Kaplowitz 2005). 
The actual downstream targets of JNK that are involved in 
APAP-induced liver injury are still largely unknown; how-
ever, a role for mitochondrial proteins has recently been 
suggested (Zhou et al. 2008).
Interestingly, 10 % of the genes from the top 1 % highly 
variable gene list consist of mitochondrial-related genes 
(see Table 1; genes in Italic). The majority of these genes 
are involved in metabolism-related processes [CCBL2 (Yu 
et al. 2006), PTPMT1 (Shen et al. 2011), ACOX3 (Cui 
et al. 2010), ACOT7 (Fujita et al. 2011), and CYB5R1 
(Chae et al. 2013)], while others are part of the respiratory 
chain complexes in the mitochondria [ATP5D (Sotgia et al. 
2012) and BCS1L (Kotarsky et al. 2012)] or are involved 
in more structurally-related processes like protein synthesis 
[MRPS26 (Sotgia et al. 2012)] and mitochondrial matrix 
or membrane maintenance [LONP1 (Tian et al. 2011) and 
TIMM9 (Sotgia et al. 2012), respectively]. All but one 
(MRPS26) of the above-mentioned genes has been related 
to the toxic/necrotic effects of APAP in a study compar-
ing the toxicity response to APAP in rats/mice with the 
response to APAP’s far less toxic stereo-isomer N-acetyl-
m-aminophenol [AMAP; (Beyer et al. 2007)]. In addition, 
ATP5D, MRPS26, LONP1, ACOT7, and TIMM9 were also 
shown to be regulated in HepG2 cells exposed to a toxic 
(10 mM) APAP dose for 12–72 h (unpublished results). 
Drug-induced liver injury has often been linked to regula-
tion of the mitochondrial stress responses, which include 
the formation of ROS products, alterations in lipid metabo-
lism, electron transport, cofactor metabolism, and the acti-
vation of pathways important in determining cell survival 
or death (Beyer et al. 2007; Han et al. 2013).
The nearest neighbor analyses on all mitochondrial-
related genes from the top 1 % highly variable gene list 
show that mainly transcription factors seem to be the bind-
ing element in the response of the mitochondrial-related 
genes (Fig. 2). The involvement of transcription factors 
has been suggested in the drug-induced stress response of 
mitochondria in hepatocytes (Han et al. 2013). This indi-
cates that interindividual variation exists in the response 
of mitochondrial-related genes, possibly explaining part of 
the differences between humans in mitochondrial-related 
APAP-induced toxicity responses and consequential liver 
damage levels.
Furthermore, in the gene set overrepresentation net-
work, another smaller network around p75NTR is present 
(Fig. 1, encircled with dotted line). P75 NTR is a cell mem-
brane receptor protein that has been associated with tumor 
and metastasis suppression (Khwaja et al. 2004), similar 
to the cluster described above. Non-steroidal anti-inflam-
matory drugs (NSAIDs) are used to reduce inflammation 
and also act as analgesics by the inhibition of cyclooxy-
genase-2 (COX-2). However, high concentrations of some 
NSAIDs are able to reduce proliferation and induce apop-
tosis in cancer cells. Several molecular mechanisms have 
been proposed as possible mediators in the anticancerous 
effects of NSAIDs, including p75NTR. Although APAP is 
not considered to be a real NSAID, due to its limited anti-
inflammatory effects, APAP does affect similar pathways 
and works as an analgesic through COX-2 inhibition which 
might explain why similar effects have been suggested for 
APAP (Bonnefont et al. 2007).
Two other components in the gene set overrepresen-
tation network that are connected to the components 
described above are the ‘Wnt-signaling pathway and pluri-
potency’ and ‘BTG family proteins and cell cycle regula-
tion’ (see Fig. 1). Both pathways can be related to APAP-
induced toxicity-related effects. The stimulation of the Wnt 
pathway has been suggested to be beneficial after APAP-
induced liver failure by stimulating liver regeneration 
(Apte et al. 2009). This corresponds with the previously 
mentioned regulation of liver regeneration by the genes 
involved in the cluster around TLRs, JNK, NF-κB, IL-1, 
p38, and cyclin D1-related pathways. The BGT gene fam-
ily has been associated with APAP hepatotoxicity before 
(Beyer et al. 2007) and has a function in DNA-strand break 
repair (Choi et al. 2012) and in the regulation of reactive 
oxygen species generation in the mitochondria (Lim et al. 
2012). Both APAP and NAPQI are known to covalently 
bind to DNA and cause DNA damage (Dybing et al. 1984; 
Rannug et al. 1995), which possibly explains why this path-
way is triggered by APAP exposure. As already described 
above, mitochondrial stress is an intricate part of the cel-
lular response to APAP-induced oxidative stress (Hanawa 
et al. 2008), which might also explain the response of the 
BTG-related pathway. These findings agree with the previ-
ously mentioned interindividual variation in mitochondrial 
genes.
In addition, several other pathways not connected to the 
main cluster of pathways are included in the network of the 
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gene set overrepresentation analysis. These are ‘leukotriene 
metabolism’ together with ‘biosynthesis of unsaturated 
fatty acids,’ ‘amino sugar and nucleotide sugar metabolism’ 
and ‘RIG-I-MDA5-mediated induction of IFN-alpha–beta.’ 
The first set of pathways (leukotrienes and fatty acids) 
probably represents the variation in the normal, therapeu-
tic mechanism of APAP. In humans, unsaturated fatty acids 
are bioactivated through enzymatic oxygenation to, among 
others, prostaglandins and leukotrienes which contribute to 
fever, pain, inflammation, and cancer development (Ricci-
otti and FitzGerald 2011). APAP interferes with these pro-
cesses as such inhibiting symptoms. Concerning the sugar 
metabolism pathway, carbohydrate homeostasis is essen-
tial for normal liver function. It is well known that during 
APAP-induced liver failure, these processes are severely 
affected (Record et al. 1975). Finally, RIG-I-MDA5-medi-
ated induction of IFN-alpha–beta is a process that has been 
linked to several liver pathologies like hepatitis A/B/C and 
hepatic steatosis (Kawai et al. 2005; Toyoda et al. 2013; 
Wei et al. 2010). Although no apparent link with APAP 
is available in the literature, it seems that this process is 
somehow linked to an APAP-induced stress response.
To determine how the variation in the above-mentioned 
genes can explain the interindividual variation in metabo-
lism levels, a correlation analysis was performed between 
the top 1 % most variable genes and all metabolites. Glu-
curonidation and sulfation are the two major processes in 
APAP metabolism, resulting in APAP-glucuronide and 
APAP-sulfate, respectively, which are non-toxic APAP 
metabolites (see Fig. 3; Chen et al. 2008a). In addition, 
another less abundant route of APAP metabolism utilizes 
hydroxylation/methoxylation of APAP. Hydroxy-APAP 
and methoxy-APAP are oxidative metabolites formed dur-
ing this route of APAP metabolism, and both these metabo-
lites have been associated with the hepatotoxic effects of 
APAP (Chen et al. 2008a; Dahlin et al. 1984b; Wilson et al. 
1982). The variation in both these metabolites could be 
explained by a large proportion of the genes from the top 
1 % most variable genes (n = 36 for both metabolites). It 
thus seems that the largest interindividual variation in gene 
expression responses after APAP exposure can be linked to 
the formation of toxic APAP metabolite formation. Inter-
estingly, hydroxy/methoxy-derived metabolites could also 
be detected in human in vivo low-dose APAP exposure 
(Jetten et al. 2012). The fact that these metabolites and their 
derivatives are detectable both in vivo and in vitro, even 
at APAP doses within the therapeutic range and that their 
variation in expression levels between individuals can be 
linked to the variation in gene expression of genes related 
to toxicity-related effects of APAP exposure, indicates a 
role as potential key elements in the molecular mechanism 
behind APAP toxicity. Additionally, another metabolite, 
C8H13O5N-APAP-glucuronide, also shows correlation with 
a large set of the top 1 % variable genes (n = 51). This 
metabolite was described as new in the low-dose in vivo 
APAP exposure study of Jetten et al. (2012). Since this 
metabolite is relatively unknown, further studies on its 
exact route of metabolism and toxic potency could lead to 
further insight into the molecular mechanism behind APAP 
toxicity for the same reasons as explained for hydroxyl/
methoxy-APAP above.
In summary, the biological processes in which the 
genes with the highest variability in expression between 
individuals after APAP exposure are involved can be 
linked to APAP-toxicity-related processes like liver regen-
eration, inflammatory responses, and mitochondrial stress 
responses. Also, processes related to hepatocarcinogenesis, 
cell cycle, and drug efficacy show large interindividual var-
iation after APAP exposure.
In addition, most of the genes with high variability 
between individuals after APAP exposure can be linked to 
variability in expression levels of metabolites (hydroxyl/
methoxy-APAP and C8H13O5N-APAP-glucuronide). Pos-
sibly, these findings could help explain the differences seen 
in susceptibility to APAP toxicity in the in vivo situation. 
Furthermore, they might give an indication for where the 
factors causing variability in susceptibility toward APAP-
induced liver failure could be found.
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